Skip to Content

Veeva Systems Inc Class A VEEV

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Veeva Beats Revenue and EPS Guidance; However, CRM Headwinds Could Dampen Short-Term Growth

Dylan Finley, CFA Equity Analyst

Analyst Note

| Dylan Finley, CFA |

Despite the positive results and a nominal bump to fiscal 2022 revenue and EPS guidance, shares fell nearly 8% after trading hours, with investors likely overreacting to management's commentary on macro trends impacting customer relationship management software (CRM) growth. We are lowering our fair value estimate from $305 to $300, as a result of changes to our short-term growth assumptions.

Read Full Analysis

Company Profile

Business Description

Veeva is a leading supplier of software solutions for the life sciences industry. The company’s best-of-breed offering addresses operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise and cloud-based platform to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning, or ERP, systems that have limited flexibility. As the vertical leader, Veeva innovates, increases wallet share at existing customers, and expands into other industries with similar regulations, protocols, and procedures, such as consumer goods, chemicals, and cosmetics.

4280 Hacienda Drive
Pleasanton, CA, 94588
T +1 925 452-6500
Sector Healthcare
Industry Health Information Services
Most Recent Earnings Jul 31, 2021
Fiscal Year End Jan 31, 2022
Stock Type Aggressive Growth
Employees 4,506